서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 56 of 56

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-08
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor
DOI
2005-12
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I-E/IIE extranodal NK/T-cell lymphoma, nasal type
DOI
2006-02
Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer
view file
2007-05
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
DOI
2008-03
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
DOI
2008-04
High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea
DOI
2012-05
Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?
DOI
2013-05
Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
DOI
2014-03
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
DOI
2014-07
Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers
DOI
2015-07
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
DOI
2017-04
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
DOI
2017-11
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
DOI
2018-11
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
DOI
2018-12
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
DOI
2019-01
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
DOI
2019-05
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
view fileDOI
2019-09
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
DOI
2019-10
Treating HR+/HER2-breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
DOI
2019-11
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
DOI
2019-12
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial
DOI
2019-12
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DOI
2020-02
Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12)
DOI
2020-02
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
DOI
2020-05
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
DOI
2020-09
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
DOI
2020-11
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
DOI
2020-12
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
DOI
2021-04
New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12)
DOI
2021-07
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Gelmon, Karen A.; Fasching, Peter A.; Couch, Fergus J.; Balmaña, Judith; Delaloge, Suzette; Labidi-Galy, Intidhar; Bennett, James; McCutcheon, Susan; Walker, Graham; O'Shaughnessy, Joyce; Collaborating Investigator; Timcheva, Constanta; Tomova, Antoaneta; Eisen, Andrea; Lemieux, Julie; Bazan, Fernando; Bourgeois, Hugues; Chakiba, Camille; Chehimi, Mohamad; Dalenc, Florence; De La Motte Rouge, Thibault; Frenel, Jean-Sébastien; Gonçalves, Anthony; Hardy-Bessard, Anne Claire; Lamy, Regine; Levy, Christelle; Lortholary, Alain; Mailliez, Audrey; Medioni, Jacques; Patsouris, Anne; Spaeth, Dominique; Teixeira, Luis; Tennevet, Isabelle; Villanueva, Cristian; You, Benoit; Ettl, Johannes; Gerber, Bernd; Hoffmann, Oliver; Park-Simon, Tjoung-Won; Reinisch, Mattea; Tio, Joke; Wimberger, Pauline; Boer, Katalin; Ballestrero, Alberto; Bianchini, Giampaolo; Biganzoli, Laura; Bordonaro, Roberto; Cognetti, Francesco; De Laurentiis, Michelino; De Placido, Sabino; Guarneri, Valentina; Montemurro, Filippo; Naso, Giuseppe; Santoro, Armando; Zamagni, Claudio; Kim, Seung-Jin; Nakamura, Seigo; Chae, Yee Soo; Cho, Eun Kyung; Hyun, Kim Jee; Im, Seock-Ah; Lee, Keun Seok; Park, Yeon Hee; Sohn, Joo Hyuk; Byrski, Tomasz; Huzarski, Tomasz; Kukielka-Budny, Bozena; Nowecki, Zbigniew; Szoszkiewicz, Renata; Tarnawski, Rafal; Dvornichenko, Viktoria; Moiseenko, Fedor; Mukhametshina, Guzel; Poddubskaya, Elena; Popova, Ekaterina; Tarasova, Anna; Vats, Anna; Adamo, Bárbara; Conejero, Raquel Andrés; Torres, Antonio Antón; Gelpi, Judith Balmaña; Fernández, Nieves Díaz; González, Alejandro Falcón; Garcia, Juan; Lorenzo-Lorenzo, Isabel; Antón, Fernando Moreno; Santisteban, Marta; Stradella, Agostina; Huang, Chiun-Sheng; Aksoy, Sercan; Arslan, Cagatay; Artac, Mehmet; Aydiner, Adnan; Ozyilkan, Ozgur; Sezer, Emel; Armstrong, Anne; Barrett, Sophie; Borley, Annabel; Kemp, Zoe; Michie, Caroline; Mukesh, Mukesh; Perren, Timothy; Swampillai, Angela; Young, Tammy

European Journal of Cancer, Vol.152, pp.68-77

DOI
2021-07
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
DOI
2021-11
EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY
DOI
2021-12
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)
DOI
2022-02
The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology
DOI
2022-03
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
DOI
2022-04
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
DOI
2022-07
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
DOI
2022-09
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
DOI
2022-10
The Pattern of Care for Brain Metastasis from Breast Cancer Over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
DOI
2023-04
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
DOI
2023-05
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)
DOI
2023-06
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer
DOI
2023-07
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
DOI
2023-07
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
DOI
2023-07
Comparison of initial and sequential salvage brain-directed treatment in patients with 1-4 vs. 5-10 brain metastases from breast cancer (KROG 16-12)
DOI
2023-07
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
view fileDOI
2023-11
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
DOI
2023-12
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Balmana, Judith; Fasching, Peter A.; Couch, Fergus J.; Delaloge, Suzette; Labidi-Galy, Intidhar; O'Shaughnessy, Joyce; Park, Yeon Hee; Eisen, Andrea F.; You, Benoit; Bourgeois, Hughes; Goncalves, Anthony; Kemp, Zoe; Swampillai, Angela; Jankowski, Tomasz; Sohn, Joo Hyuk; Poddubskaya, Elena; Mukhametshina, Guzel; Aksoy, Sercan; Timcheva, Constanta V.; Park-Simon, Tjoung-Won; Anton-Torres, Antonio; John, Ellie; Baria, Katherine; Gibson, Isabel; Gelmon, Karen A.; Koynova, Tatyana; Popov, Vasil; Timcheva, Constanta; Tomova, Antoaneta; Eisen, Andrea; Gelmon, Karen; Lemieux, Julie; Augereau, Paule; Bazan, Fernando; Becuwe, Celia; Bourgeois, Hugues; Chakiba, Camille; Chehimi, Mohamad; Cheneau, Caroline; Dalenc, Florence; de Guillebon, Eleonore; de la Motte Rouge, Thibault; Frenel, Jean-Sebastien; Goncalves, Anthony; Grenier, Julien; Hardy-Bessard, Anne Claire; Lamy, Regine; Levy, Christelle; Lortholary, Alain; Mailliez, Audrey; Medioni, Jacques; Patsouris, Anne; Spaeth, Dominique; Teixeira, Luis; Tennevet, Isabelle; Venat-Bouvet, Laurence; Villanueva, Cristian; You, Benoit; Ettl, Johannes; Fasching, Peter; Gerber, Bernd; Hanusch, Claus Alexander; Hoffmann, Oliver; Park-Simon, Tjoung-Won; Malter, Wolfram; Reinisch, Mattea; Tio, Joke; Wimberger, Pauline; Boer, Katalin; Dank, Magdolna; Ballestrero, Alberto; Bianchini, Giampaolo; Biganzoli, Laura; Bordonaro, Roberto; Cognetti, Francesco; Cortesi, Enrico; De Laurentiis, Michelino; De Placido, Sabino; Gianni, Luca; Guarneri, Valentina; Marchetti, Paulo; Montemurro, Filippo; Mosconi, Anna Maria; Naso, Giuseppe; Puglisi, Fabio; Santoro, Armando; Zamagni, Claudio; Iwata, Hiroji; Kim, Seung-Jin; Nakamura, Seigo; Chae, Yee Soo; Cho, Eun Kyung; Kim, Jee Hyun; Im, Seock-Ah; Lee, Keun Seok; Park, Yeon Hee; Sohn, Joo Hyuk; Byrski, Tomasz; Huzarski, Tomasz; Jankowski, Tomasz; Kukielka-Budny, Bozena; Lacko, Aleksandra; Nowecki, Zbigniew; Senkus-Konefka, Elzbieta; Szoszkiewicz, Renata; Tarnawski, Rafal; Andabekov, Timur; Dvorkin, Mikhail; Dvornichenko, Viktoria; Moiseenko, Fedor; Mukhametshina, Guzel; Poddubskaya, Elena; Popova, Ekaterina; Tarasova, Anna; Sakaeva, Dina; Shomova, Marina; Vats, Anna; Adamo, Barbara; Conejero, Raquel Andres; Torres, Antonio Anton; Gelpi, Judith Balmana; de Ibarguen, Blanca Cantos Sanchez; Jurado, Josefina Cruz; Fernandez, Nieves Diaz; Gonzalez, Alejandro Falcon; Garcia, Juan; Santiago, Santiago Gonzalez; Carrasco, Fernando Henao; Lorenzo, Isabel Lorenzo; Anton, Fernando Moreno; Garcia, Beatriz Rojas; Beltran, Salomon Menjon; Santisteban, Marta; Stradella, Agostina; Hou, Ming-Feng; Huang, Chiun-Sheng; Lin, Yung-Chang; Tseng, Ling-Ming; Wang, Hwei-Chung; Aksoy, Sercan; Arslan, Cagatay; Artac, Mehmet; Aydiner, Adnan; Disel, Umut; Ozkan, Metin; Ozyilkan, Ozgur; Sezer, Emel Yaman; Yetisyigit, Tarkan; Armstrong, Anne; Barrett, Sophie; Borley, Annabel; Kemp, Zoe; Michie, Caroline; Mukesh, Mukesh; Perren, Timothy; Swampillai, Angela; Chaudhry, Madhu; Young, Tammy

BREAST CANCER RESEARCH AND TREATMENT

DOI
2023-12
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
DOI
2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
DOI
2024-01
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
DOI
2024-01
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer
view fileDOI
2024-06
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study
DOI
2024-06
Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
DOI
2024-08
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
DOI
2024-09
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
DOI
1